Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-30

Clinical Trial Update: Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of Turoctocog alfa for prevention and treatment of bleeds in previously untreated children with Haemophilia A has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Turoctocog alfa (turoctocog alfa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2018-10-30